30 results match your criteria: "Mayo Foundation and Mayo Clinic[Affiliation]"
J Clin Oncol
December 2004
Division of Medical Oncology, Department of Medicine, Mayo Foundation and Mayo Clinic College of Medicine, Rochester, MN, USA.
Purpose: To describe the prevalence, clinical characteristics, and pattern of use of complementary and alternative medicine (CAM) in patients enrolled onto phase I trials.
Patients And Methods: Questionnaires were administered to 108 patients with advanced malignancies enrolled onto phase I chemotherapy trials at the Mayo Clinic Comprehensive Cancer Center (Rochester, MN). CAM was classified into two modalities, pharmacologic and nonpharmacologic.
Dis Colon Rectum
October 2004
Clinical Enteric Neuroscience Translational and Epidemiologic Research (CENTER) Program, Mayo Foundation and Mayo Clinic, Rochester, Minnesota, USA.
Background: We hypothesized that functional anal incontinence with no structural explanation comprises distinct pathophysiologic subgroups that could be identified on the basis of the predominant presenting bowel pattern.
Methods: Consecutive patients (n = 80) were prospectively grouped by bowel symptoms as 1) incontinence only, 2) incontinence + constipation, 3) incontinence + diarrhea, and 4) incontinence + alternating bowel symptoms. The Hopkins Bowel Symptom Questionnaire, the Symptom Checklist 90-R, and anorectal manometry were completed.
Curr Opin Investig Drugs
January 2004
Mayo Foundation and Mayo Clinic, GI Physiology & Motility, Division of Gastroenterology & Hepatology, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA.
Disorders of gastrointestinal function are common and significantly reduce quality-of-life, as well as negatively impacting healthcare costs. Consequently, there is much interest in understanding the pathogenesis of these disorders. Increasing, albeit as yet limited, evidence has implicated alterations in 5-hydroxytryptamine (5-HT) release, and the subsequent interaction of 5-HT with specific 5-HT receptor subtypes, in the altered gut function of patients with irritable bowel syndrome (IBS) and other functional bowel diseases.
View Article and Find Full Text PDFJ Membr Biol
July 2002
Mayo Foundation and Mayo Clinic Scottsdale, S. C. Johnson Medical Research Center, 13400 E. Shea Blvd., Scottsdale, AZ 85259, USA.
Although the CFTR protein alone is sufficient to generate a regulated chloride channel, it is unknown how many of the polypeptides form the channel. Using biochemical and functional assays, we demonstrate that the CFTR polypeptide is a monomer. CFTR sediments as a monomer in a linear, continuous sucrose gradient.
View Article and Find Full Text PDFJ Thorac Cardiovasc Surg
May 2002
Division of Cardiothoracic Surgery, Mayo Foundation and Mayo Clinic, Rochester, Minn., 55905, USA.
Background: The purpose of this investigation was to determine whether temperatures of the aortic arch and descending aortic circulations could be controlled independently during cardiopulmonary bypass with a cannula possessing an endoaortic baffle (Cobra; Cardeon, Cupertino, Calif).
Methods: After Institutional Animal Care and Use Committee approval, 12 pigs weighing 60 kg were started on bypass through a sternotomy. A dual-lumen endoaortic cannula with a deployable baffle was used for arterial cannulation.
Biochem J
September 2002
Mayo Foundation and Mayo Clinic Scottsdale, S. C. Johnson Medical Research Center, 13400 E. Shea Blvd., Scottsdale, AZ 85259, USA.
The cystic fibrosis transmembrane conductance regulator (CFTR) contains two nucleotide-binding domains (NBDs) or ATP-binding cassettes (ABCs) that characterize a large family of membrane transporters. Although the three-dimensional structures of these domains from several ABC proteins have been determined, this is not the case for CFTR, and hence the domains are defined simply on the basis of sequence alignment. The functional C-terminal boundary of NBD1 of CFTR was located by analysis of chloride channel function [Chan, Csanady, Seto-Young, Nairn and Gadsby (2000) J.
View Article and Find Full Text PDFFEBS Lett
May 2002
Mayo Foundation and Mayo Clinic Scottsdale, S.C. Johnson Medical Research Center, 13400 E. Shea Blvd., Scottsdale, AZ 85259, USA.
Alterations in the pentose ring of ATP have a major impact on cystic fibrosis transmembrane conductance regulator (CFTR) function. Both 2'- and 3'-deoxy-ATP (dATP) accelerate ion channel openings and stabilize open channel structure better than ATP. Purified wild-type CFTR hydrolyzes dATP.
View Article and Find Full Text PDFJ Biol Chem
May 2002
Mayo Foundation and Mayo Clinic Scottsdale, S. C. Johnson Medical Research Center, Scottsdale, Arizona 85259, USA.
As in other adenine nucleotide binding cassette (ABC) proteins the nucleotide binding domains of the cystic fibrosis transmembrane conductance regulator (CFTR) bind and hydrolyze ATP and in some manner regulate CFTR ion channel gating. Unlike some other ABC proteins, however, there are preliminary indications that the two domains of CFTR are nonequivalent in their nucleotide interactions (Szabo, K., Szakacs, G.
View Article and Find Full Text PDFAnn Thorac Surg
January 2002
Department of Anesthesiology, Mayo Foundation and Mayo Clinic, Rochester, Minnesota, USA.
Background: Cerebral embolization during cardiopulmonary bypass is an important cause of neurologic injury. This study determined whether an endoaortic baffle catheter (Cardeon Cobra Catheter; Cardeon Corporation, Cupertino, CA) could substantially reduce cerebral embolization in a swine cardiopulmonary bypass model.
Methods: Sixteen 60 kg pigs underwent cardiopulmonary bypass; 8 animals with the Cobra baffle (Cardeon Corporation, Cupertino, CA) deployed, and 8 with the same cannula without baffle deployment.
Semin Thorac Cardiovasc Surg
April 2001
Department of Anesthesiology, Mayo Medical School, Mayo Foundation and Mayo Clinic, Rochester, MN 55905, USA.
Temperature management during cardiac surgery deserves considerable attention because it has broad effects, altering virtually every physiologic process, including oxygen demand, blood flow, cardiac output, and coagulation. Temperature is also important in cardiac surgery because virtually all patients undergo significant temperature change. These changes can be unique in mammalian physiology both with regard to their magnitude and rate of change.
View Article and Find Full Text PDFCancer Invest
May 2001
Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, USA.
Doxorubicin and paclitaxel are highly active agents in the treatment of advanced breast cancer. Although early trials of the combination reported high response rates, an unexpectedly high incidence of congestive heart failure observed on two of the early trials was cause for much concern. More recently, clinical trials that have limited the cumulative doxorubicin dose to 400 mg/m2 or below when given in combination with paclitaxel have not observed an increase in cardiac toxicity.
View Article and Find Full Text PDFSemin Oncol
December 2000
Division of Hematology/Oncology, Mayo Foundation and Mayo Clinic, Jacksonville, FL, USA.
HER-2 (c-erbB-2, neu) is an important prognostic and predictive factor in breast cancer. Clinical trials utilizing a humanized version of the anti-HER-2 murine monoclonal antibody 4DS, trastuzumab (Herceptin; Genentech Inc, South San Francisco, CA), have shown antitumor activity in patients with HER-2-positive metastatic breast cancer. Improved response and survival rates have been shown when trastuzumab was added to first-line combination chemotherapy with anthracycline/cyclophosphamide or paclitaxel, compared to the same chemotherapy alone.
View Article and Find Full Text PDFAnn Thorac Surg
November 2000
Department of Surgery, Mayo Foundation and Mayo Clinic, Rochester, Minnesota 55905, USA.
Intracardiac ectopic thyroid is a rare lesion. We present a case of successful excision of thyroid tissue obstructing the right ventricular outflow tract and provide a literature review. In all cases reported to date, the ectopic tissue arose from the ventricular septum and extended to the outflow tract.
View Article and Find Full Text PDFAnn Thorac Surg
May 2000
Division of Cardiothoracic Surgery, Mayo Foundation and Mayo Clinic, Rochester, Minnesota 55905, USA.
Background: The purpose of this study was to determine the feasibility of differential perfusion of the aortic arch and descending aorta during cardiopulmonary bypass using a cannula designed for aortic segmentation.
Methods: Pigs weighing 57 kg (n = 8), underwent cardiopulmonary bypass using the dual lumen aortic cannula. An inflatable balloon separated proximal (aortic arch) and distal (descending aorta) ports.
Ann Thorac Surg
April 2000
Department of Anesthesiology, Mayo Foundation and Mayo Clinic, Rochester, Minnesota 55905, USA.
Background: Embolization during cardiopulmonary bypass probably alters cerebral autoregulation. Therefore, using laser Doppler flowmetry we investigated the cerebral blood flow velocity changes in response to changes in arterial pressure, before and after embolization in a canine bypass model.
Methods: After Institutional Animal Care and Use Committee approval, 8 anesthetized dogs had a laser Doppler flow probe positioned over the temporoparietal dura.
Cancer Control
May 1999
Division of Hematology/Oncology, Mayo Foundation and Mayo Clinic, Jacksonville, Florida 32224, USA.
BACKGROUND: An expanded understanding of the biology of breast cancer has led to the identification of the HER-2 receptor as an important growth factor. This receptor possesses intrinsic tyrosine kinase activity and has been associated with aggressive biological behavior and poor clinical outcome. METHODS: Data have been reviewed regarding the role of HER-2 expression as a prognostic variable, as a predictive factor for response to chemotherapy and hormonal therapies, and as a directed therapeutic target for breast cancer.
View Article and Find Full Text PDFAnn Thorac Surg
February 2000
Department of Anesthesiology, Mayo Foundation and Mayo Clinic, Rochester, Minnesota 55905, USA.
Background: Patients experience cerebral embolization during cardiopulmonary bypass (CPB). This study determined if alterations in temperature and/or PaCO2 can reduce cerebral and ocular embolization.
Methods And Results: Forty-four pigs underwent CPB: 24 animals at 28 degrees C, and 20 at 38 degrees C.
J Cardiothorac Vasc Anesth
February 2000
Department of Anesthesiology, Mayo Foundation and Mayo Clinic, Rochester, MN, USA.
Objective: To determine if normal cardiopulmonary bypass (CPB) pump flows maintain cerebral perfusion in the context of reduced mean arterial pressure at 33 degrees C.
Design: A prospective investigation.
Setting: Animal CPB research laboratory.
Breast Cancer Res Treat
September 1999
Division of Hematology/Oncology, Mayo Foundation and Mayo Clinic Jacksonville, Florida 32224, USA.
Antiemetic treatment should be considered for breast cancer patients receiving moderately emetogenic chemotherapy. Although the extent of chemotherapy-induced emesis is largely dependent on the emetogenic potential of the specific agents employed, patient characteristics such as age and sex also contribute. Recent clinical studies show that treatment with the currently available 5-HT3 antagonists effectively reduces the incidence of chemotherapy-induced nausea and vomiting and improves quality of life in a substantial number of these patients.
View Article and Find Full Text PDFAnesthesiology
November 1999
Department of Anesthesiology, Mayo Foundation and Mayo Clinic, Rochester, Minnesota 55905, USA.
Background: Cerebral embolization is a primary cause of cardiac surgical neurologic morbidity. During cardiopulmonary bypass (CPB), there are well-defined periods of embolic risk. In theory, cerebral embolization might be reduced by an increase in pump flow during these periods.
View Article and Find Full Text PDFSemin Oncol
August 1999
Mayo Foundation and Mayo Clinic Jacksonville, FL 32224, USA.
The medical approach to the management of metastatic breast cancer has changed through the years following the introduction of new cytotoxic agents and the demonstration of their antitumor activity. In general, combination drug regimens are the initial treatments of choice when chemotherapy is indicated for patients with metastatic breast cancer. However, the single-agent activity of some of the newer agents rivals that of older combination chemotherapy treatments.
View Article and Find Full Text PDFOncologist
January 1998
Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, 32224, USA.
Paclitaxel has emerged as an important agent in the treatment of breast cancer. The efficacy and tolerability of this agent, as well as its lack of cross-resistance with anthracyclines, have spurred intensive clinical investigation worldwide. Optimization of paclitaxel dose and scheduling and evaluation of the drug in combination regimens are a central focus of investigations.
View Article and Find Full Text PDFSemin Oncol
February 1999
Division of Hematology/Oncology, Mayo Foundation and Mayo Clinic, Jacksonville, FL 32224, USA.
The results of several phase II and some phase III studies are now available in which the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and nonanthracycline agents are evaluated. The studies demonstrate the activity and feasibility of these combinations, which achieved response rates of 40% to 80% and median time to progression that exceeded 6 months. The potential role of these combinations compared with older non-paclitaxel-containing regimens, in improving quality of life, response rate, and survival in patients with metastatic breast cancer, however, await the results of prospective, randomized phase III trials.
View Article and Find Full Text PDFAm J Pathol
February 1999
Department of Laboratory Medicine and Pathology, Mayo Foundation and Mayo Clinic, Rochester, Minnesota 55905, USA.
p27kip1 (p27) is a member of the universal cyclin-dependent kinase inhibitor (CDKI) family. p27 expression is regulated by cell contact inhibition and by specific growth factors, such as transforming growth factor (TGF)-beta. Since the cloning of the p27 gene in 1994, a host of other functions have been associated with this cell cycle protein.
View Article and Find Full Text PDFAnesthesiology
January 1999
Department of Anesthesiology, Mayo Foundation and Mayo Clinic, Rochester, Minnesota 55905, USA.
Background: Patients undergoing cardiac surgery have a substantial incidence of neurologic complications related to cerebral embolization during cardiopulmonary bypass. The purpose of this study was to determine if adjustments in the arterial carbon dioxide (PaCO2) level can reduce cerebral and ocular embolization.
Methods: Twenty pigs underwent cardiopulmonary bypass at 38 degrees C.